150 related articles for article (PubMed ID: 37986364)
1. Neoadjuvant chemotherapy combined with endocrine therapy for hormone receptor-positive breast cancer: A systematic review and meta-analysis.
Ma HF; Shen J; Xu B; Shen JG
Medicine (Baltimore); 2023 Nov; 102(46):e35928. PubMed ID: 37986364
[TBL] [Abstract][Full Text] [Related]
2. Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trial.
Yu KD; Wu SY; Liu GY; Wu J; Di GH; Hu Z; Hou YF; Chen CM; Fan L; Tang LC; Shen ZZ; Wu KJ; Zhuang ZG; Zhang HW; Shao ZM
Cancer; 2019 Jul; 125(13):2185-2193. PubMed ID: 30892700
[TBL] [Abstract][Full Text] [Related]
3. The tumour response of postmenopausal hormone receptor-positive breast cancers undergoing different types of neoadjuvant therapy: a meta-analysis.
Wang Y; He L; Song Y; Wu Q; Wang H; Zhang B; Ma X
BMC Womens Health; 2020 Jan; 20(1):17. PubMed ID: 32005117
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of neoadjuvant chemotherapy combined with bevacizumab versus neoadjuvant chemotherapy alone for Her2-negative breast cancer: a meta-analysis of randomized controlled clinical trials].
Han R; Wang G; Zhang Y; Zhao X
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 May; 45(4):379-386. PubMed ID: 27868411
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of concomitant chemo-endocrine therapy in neoadjuvant treatment of hormone-positive HER2-negative breast cancer: a systemic review and meta-analysis.
Ergun Y; Ucar G; Akagündüz B
Expert Opin Drug Saf; 2023 Apr; 22(4):313-322. PubMed ID: 37057733
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of neoadjuvant therapy for HR-positive/HER2-negative early breast cancer: a Bayesian network meta-analysis.
Chen R; Yu Y; Zhang J; Song C; Wang C
Expert Rev Anticancer Ther; 2024 Jul; 24(7):599-611. PubMed ID: 38693054
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER2- Breast Cancer: A Systematic Review and Meta-Analysis.
Hong K; Yao L; Sheng X; Ye D; Guo Y
Oncol Res Treat; 2021; 44(10):557-567. PubMed ID: 34515204
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent kinase 4 and 6 inhibitors in combination with neoadjuvant endocrine therapy in estrogen receptor-positive early breast cancer: a systematic review and meta-analysis.
Guan Y; Shen G; Fang Q; Xin Y; Huo X; Li J; Zhao F; Ren D; Liu Z; Li Z; Zhao J
Clin Exp Med; 2023 Jun; 23(2):245-254. PubMed ID: 35304677
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant and neoadjuvant therapy with cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic review and meta-analysis.
Zhang M; Song J; Guo S; Jin F; Zheng A
Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37283514
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, advanced breast cancer: a systematic review and meta-analysis.
Dai Q; Wang Y; Liao M; Chen H
Ann Palliat Med; 2022 Dec; 11(12):3727-3742. PubMed ID: 36635998
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials.
Cao L; Yao GY; Liu MF; Chen LJ; Hu XL; Ye CS
PLoS One; 2015; 10(12):e0145442. PubMed ID: 26717149
[TBL] [Abstract][Full Text] [Related]
12. Concurrent neoadjuvant endocrine therapy with chemotherapy in HR+HER2- breast cancer: a systematic review and meta-analysis.
Wu P; Lv W
Front Endocrinol (Lausanne); 2024; 15():1254213. PubMed ID: 38481446
[TBL] [Abstract][Full Text] [Related]
13. Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review.
Wang C; Chen J; Xu X; Hu X; Kong D; Liang G; Wang X
Technol Cancer Res Treat; 2020; 19():1533033820960721. PubMed ID: 32990165
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer.
Kim HJ; Noh WC; Lee ES; Jung YS; Kim LS; Han W; Nam SJ; Gong G-; Kim HJ; Ahn SH
Breast Cancer Res; 2020 May; 22(1):54. PubMed ID: 32460816
[TBL] [Abstract][Full Text] [Related]
15. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
16. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
Solinas C; Ceppi M; Lambertini M; Scartozzi M; Buisseret L; Garaud S; Fumagalli D; de Azambuja E; Salgado R; Sotiriou C; Willard-Gallo K; Ignatiadis M
Cancer Treat Rev; 2017 Jun; 57():8-15. PubMed ID: 28525810
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes.
Cao L; Sugumar K; Keller E; Li P; Rock L; Simpson A; Freyvogel M; Montero AJ; Shenk R; Miller ME
Ann Surg Oncol; 2021 Oct; 28(10):5730-5741. PubMed ID: 34342757
[TBL] [Abstract][Full Text] [Related]
18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
19. Comparative Toxicities of Neoadjuvant Chemotherapy With or Without Bevacizumab in HER2-Negative Breast Cancer Patients: A Meta-analysis.
Wang BC; Fu C; Xie LK; Kuang BH; Zhao YX
Ann Pharmacother; 2020 Jun; 54(6):517-525. PubMed ID: 31855061
[No Abstract] [Full Text] [Related]
20. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
